HLB Therapeutics financials at a glance

+ Portfolio

The revenue of HLB Therapeutics is reported as 42.92978 billion Won in the fiscal year 2020. The earnings were -309.93 Won per share in 2020, which was 438.8 lower than 2018. And about -11.73642 billion Won are reported as free cash flow in the financials of HLB Therapeutics 2020. No dividends were paid to the shareholders of the HLB Therapeutics stock KOSDAQ:A115450 in the financial year 2020.

Forecast

Stock Value

Financials

Profile

Financials

Year	Year	TTM	2020	2018	2017
Rev.	Revenue	N/A	₩42.93B	₩46.36B	₩17.15B
GM %	Gross Margin %	16.02%	15.06%	12.28%	14.66%
OM	Operating Margin	-18.14%	-26.24%	-7.24%	-26.18%
EPS	Earnings Per Share	₩-65.24	₩-,309.93	₩91.48	₩-,100.82
Div.	Dividends	N/A	₩0.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	0	0	0
Sha.	Shares	N/AM	57.08M	51.81M	48.91M
OCF	Operating Cash Flow	N/A	₩-11,650.88M	₩-3,525.98M	₩0.00M
FCF	Free Cash Flow	N/A	₩-11,736.42M	₩-3,748.68M	₩0.00M
FCFS	Free Cash Flow Per Share	₩-,309.71	₩-,775.23	₩-,228.19	₩-,883.94

HLB Therapeutics financials at a glance

Financials

Discover